Free Trial

Accelerate Diagnostics (AXDX) Stock Price, News & Analysis

-0.12 (-9.38%)
(As of 06/18/2024 ET)
Today's Range
50-Day Range
52-Week Range
82,951 shs
Average Volume
105,008 shs
Market Capitalization
$25.58 million
P/E Ratio
Dividend Yield
Price Target

Accelerate Diagnostics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
13.8% Downside
$1.00 Price Target
Short Interest
3.52% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
-0.50mentions of Accelerate Diagnostics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$82,574 Sold Last Quarter
Proj. Earnings Growth
From ($2.37) to ($1.91) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.07 out of 5 stars

Medical Sector

513th out of 913 stocks

Analytical Instruments Industry

16th out of 28 stocks

AXDX stock logo

About Accelerate Diagnostics Stock (NASDAQ:AXDX)

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.

AXDX Stock Price History

AXDX Stock News Headlines

[Urgent] Protect your money before November
Those who listened to his warnings could have kept their money safe and even made substantial profits during each crisis. In fact, the Wall Street Journal reported that his work was more accurate … and more profitable than that of … Deutsche Bank … Merrill Lynch … JPMorgan Chase … Goldman Sachs … and every other firm reviewed.
TruBridge: Q1 Earnings Snapshot
Accelerate Diagnostics Reports Q1 Loss, Misses Revenue Estimates
[Urgent] Protect your money before November
Those who listened to his warnings could have kept their money safe and even made substantial profits during each crisis. In fact, the Wall Street Journal reported that his work was more accurate … and more profitable than that of … Deutsche Bank … Merrill Lynch … JPMorgan Chase … Goldman Sachs … and every other firm reviewed.
Q1 2024 Accelerate Diagnostics Inc Earnings Call
Accelerate Diagnostics earnings preview: what to expect
Accelerate Rural Indiana announces $30 million award
See More Headlines
Receive AXDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Accelerate Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Analytical instruments
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
2 Analysts


Net Income
Net Margins
Pretax Margin


Sales & Book Value

Annual Sales
$12.06 million
Book Value
($1.37) per share


Free Float
Market Cap
$25.58 million
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

AXDX Stock Analysis - Frequently Asked Questions

Should I buy or sell Accelerate Diagnostics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accelerate Diagnostics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AXDX shares.
View AXDX analyst ratings
or view top-rated stocks.

What is Accelerate Diagnostics' stock price target for 2024?

2 brokerages have issued 1 year target prices for Accelerate Diagnostics' stock. Their AXDX share price targets range from $1.00 to $1.00. On average, they expect the company's stock price to reach $1.00 in the next year. This suggests that the stock has a possible downside of 13.8%.
View analysts price targets for AXDX
or view top-rated stocks among Wall Street analysts.

How have AXDX shares performed in 2024?

Accelerate Diagnostics' stock was trading at $3.92 at the beginning of the year. Since then, AXDX shares have decreased by 70.4% and is now trading at $1.16.
View the best growth stocks for 2024 here

When is Accelerate Diagnostics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024.
View our AXDX earnings forecast

How were Accelerate Diagnostics' earnings last quarter?

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) posted its quarterly earnings data on Wednesday, May, 8th. The medical research company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.72) by $0.16. The medical research company had revenue of $2.92 million for the quarter, compared to analyst estimates of $3 million.

When did Accelerate Diagnostics' stock split?

Accelerate Diagnostics shares reverse split on the morning of Wednesday, July 12th 2023. The 1-10 reverse split was announced on Wednesday, July 12th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Accelerate Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Accelerate Diagnostics investors own include Himax Technologies (HIMX), Magnachip Semiconductor (MX), Fluidigm (FLDM), Universal Display (OLED), Gilead Sciences (GILD), BIOLASE (BIOL), Alibaba Group (BABA), AT&T (T), AbbVie (ABBV) and Micron Technology (MU).

Who are Accelerate Diagnostics' major shareholders?

Accelerate Diagnostics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Griffin Asset Management Inc. (6.25%), Oracle Investment Management Inc. (0.19%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David Patience, Hany Massarany, Jack Phillips, Jack W Schuler, Larry Michael Mertz, Ron Price and Steven Reichling.
View institutional ownership trends

How do I buy shares of Accelerate Diagnostics?

Shares of AXDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AXDX) was last updated on 6/19/2024 by Staff

From Our Partners